[HTML][HTML] Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma …
J Lu, W Fu, W Li, J Hu, G An, Y Wang, C Fu… - … Myeloma and Leukemia, 2021 - Elsevier
Background Daratumumab plus bortezomib/dexamethasone (D-Vd) significantly improved
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase …
J Lu, W Fu, W Li, J Hu, G An, Y Wang, C Fu… - … Myeloma & Leukemia, 2021 - europepmc.org
Background Daratumumab plus bortezomib/dexamethasone (D-Vd) significantly improved
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
[HTML][HTML] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma …
J Lu, W Fu, W Li, J Hu, G An… - Clinical …, 2021 - clinical-lymphoma-myeloma …
Background Daratumumab plus bortezomib/dexamethasone (D-Vd) significantly improved
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase …
J Lu, W Fu, W Li, J Hu, G An, Y Wang… - Clinical Lymphoma …, 2021 - search.ebscohost.com
Daratumumab plus bortezomib/dexamethasone (D-Vd) significantly improved outcomes
versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the phase 3 …
versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the phase 3 …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase …
J Lu, W Fu, W Li, J Hu, G An, Y Wang… - Clinical lymphoma …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Daratumumab plus bortezomib/dexamethasone (D-Vd) significantly improved
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
outcomes versus Vd in patients with relapsed or refractory multiple myeloma (RRMM) in the …
[引用][C] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma …
J Lu, W Fu, W Li, J Hu, G An, Y Wang, C Fu… - Clinical Lymphoma …, 2021 - cir.nii.ac.jp
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in
Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) …
Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) …